<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994030</url>
  </required_header>
  <id_info>
    <org_study_id>BDMD 6-2018</org_study_id>
    <nct_id>NCT02994030</nct_id>
  </id_info>
  <brief_title>Biomarker for Duchenne Muscular Dystrophy</brief_title>
  <acronym>BioDuchenne</acronym>
  <official_title>Biomarker for Duchenne Muscular Dystrophy: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to identify biomarker/s for&#xD;
      Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and&#xD;
      long-term variability of these biomarker/s.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duchenne Muscular Dystrophy (DMD) is a devastating inherited neuromuscular disorder that&#xD;
      affects 1 in 3300 live male births (females can be mildly affected carriers). DMD causes&#xD;
      progressive weakness and loss of muscle mass, with symptoms usually appearing in early&#xD;
      childhood. DMD arises from mutations in the DMD gene that codes for dystrophin.&#xD;
&#xD;
      The DMD gene is located on the short arm of chromosome X (locus Xp21) and codes for&#xD;
      dystrophin, containing 3685 amino acid residues. 60-65% of DMD mutations are large&#xD;
      dele-tions, 10-30% are nonsense and frame-shift mutations, 5-15% are duplications, and 2% are&#xD;
      intronic or 5'- and 3'-UTR alterations.Dystrophin aggregates as a homotetramer in the&#xD;
      skeletal muscles or associates with actin and Dystrophin-Associated Glycoproteins (DAGs),&#xD;
      forming a stable complex that interacts with laminin in the extracellular matrix. Dystrophin&#xD;
      is considered a key structural element in the muscle fiber, whose primary function is to&#xD;
      stabilize plasma mem-brane, while the DAGs maintain the sarcolemmal stability by mediating&#xD;
      the complex interactions of the muscle membrane and extracellular environment. The low levels&#xD;
      of dystrophin lead to cellular instability and progressive leakage of intracellular&#xD;
      components, explaining the characteristically high levels of creatine phosphokinase (CPK) in&#xD;
      the blood of DMD patients.&#xD;
&#xD;
      Biomarkers serve as measurable indicators of normal biological or pathological processes.&#xD;
      They are typically directly linked to genetic variants in specific genes and can predict,&#xD;
      diagnose, monitor, and assess the severity of a disease. It is the goal of this study to&#xD;
      identify, validate, and monitor biochemical markers from DMD affected participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of DMD biomarker/s</measure>
    <time_frame>36 weeks</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and long-term variability of DMD biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Increased Lordosis/Scoliosis</condition>
  <condition>Hyporeflexia</condition>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Red-Green Color Blindness</condition>
  <condition>Lordosis</condition>
  <condition>Scoliosis</condition>
  <condition>Muscular Atrophy</condition>
  <condition>Muscular Weakness</condition>
  <arm_group>
    <arm_group_label>Participants with Duchenne Muscular Dystrophy (DMD)</arm_group_label>
    <description>Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (CentocardÂ®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Duchenne Muscular Dystrophy (DMD)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Informed consent is obtained from the parent/ legal guardian&#xD;
&#xD;
          -  The participant is aged between 2 months and 50 years&#xD;
&#xD;
          -  The diagnosis of DMD is genetically confirmed by CENTOGENE&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Informed consent is not obtained from the parent/ legal guardian.&#xD;
&#xD;
          -  The participant is younger than 2 months or older than 50 years&#xD;
&#xD;
          -  The diagnosis of DMD is not genetically confirmed by CENTOGENE&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof.Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Centogene GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sana Iftikhar</last_name>
    <phone>+49 381 80113 544</phone>
    <email>sana.iftikhar@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>10001</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paskal Cullufi, MD</last_name>
      <phone>+35 5672043840</phone>
      <email>paskalcullufi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paskal Cullufi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric,Faculty of Medicine, Alexandria University Children's Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Elsayed Omar, MD</last_name>
      <phone>+20 2035826512</phone>
      <email>Tarek.Omar@alexmed.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Tarek Elsayed Omar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams University-Medical Genetics</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solaf Mohamed El Sayed, MD</last_name>
      <phone>+20 (0)1060260052</phone>
      <email>elsayed683@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Solaf Mohamed El Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omnia El Rashidy, MD</last_name>
      <phone>+20 (0)0224512900</phone>
      <email>omniarashidy@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Omnia El Rashidy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams Univirsity</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoda Tomoum, MD</last_name>
      <phone>+20 (0)0224156526</phone>
      <email>hodatomoum@gmail.com</email>
    </contact>
    <contact_backup>
      <email>mennahshata@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hoda Tomoum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Departmnet of Pediatrics, Tanta University</name>
      <address>
        <city>Tanta</city>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heba Dawoud, MD</last_name>
      <phone>+20 1094623100</phone>
      <email>hebadawoud173@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Heba Dawoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tinatin Tkemaladze, MD</last_name>
      <phone>+99 5032917304</phone>
      <email>tikatkem@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tinatin Tkemaladze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <phone>+91 (0)4842851234</phone>
      <email>sheelanampoothiri@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American of science and technology</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Megarbane, MD</last_name>
      <phone>+33 (0)610403851</phone>
      <email>andre.megarbane@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Andre Megarbane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health</name>
      <address>
        <city>Lahore</city>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huma Cheema, MD</last_name>
      <phone>+92 3009447550</phone>
      <email>pedgilahore@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Huma Cheema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Hospital for Children &quot;Louis Turcanu&quot;</name>
      <address>
        <city>TimiÅoara</city>
        <zip>682041</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Chirita, MD</last_name>
      <phone>+40 (0)732890217</phone>
      <email>adela.chirita@umft.ro</email>
    </contact>
    <investigator>
      <last_name>Adela Chirita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo 8</city>
        <zip>300011</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eresha Jasinge, MD</last_name>
      <phone>+94 (0)712793328</phone>
      <email>eresha.jasinge@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eresha Jasinge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Egypt</country>
    <country>Georgia</country>
    <country>India</country>
    <country>Lebanon</country>
    <country>Pakistan</country>
    <country>Romania</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Lithuania</country>
    <country>United Arab Emirates</country>
  </removed_countries>
  <link>
    <url>http://centogene.com</url>
    <description>Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Disease</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Scoliosis</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Lordosis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Color Vision Defects</mesh_term>
    <mesh_term>Reflex, Abnormal</mesh_term>
    <mesh_term>Swayback</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

